Patheon to Acquire Banner Pharmacaps - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Patheon to Acquire Banner Pharmacaps



Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million. The acquisition will provide Patheon with several new products, technologies and facilities, and is also in line with the company’s intention to further develop its oral dosage development and manufacturing services.

According to a press statement, Banner Pharmacaps is the second largest pharmaceutical business in the world focused on developing softgel formulations. The company has research laboratories and manufacturing facilities in the US, the Netherlands, Canada and Mexico.

James C. Mullen, CEO of Patheon, said in the statement, “The transaction provides is with a well-balanced portfolio of proprietary products, state-of-the-art facilities with enhanced capabilities, as well as an expanded geographical presence. We believe our visibility with in the industry will be further strengthened as we pass the $1-billion revenue mark.”

Patheon is purchasing Banner Pharmacaps from VION N.V., a manufacturer of foodstuffs and ingredients based in the Netherlands. VION intends to now focus on its core business in the food industry.

The acquisition is expected to close by the end of this year.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here